Therapeutic Inhibition of miR-4260 Suppresses Colorectal Cancer via Targeting MCC and SMAD4

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• MicroRNA (miRNA) dysregulation is implicated in colorectal cancer (CRC) development.
• The specific miRNAs targeting the tumor suppressor gene Mutated in Colorectal Cancer (MCC) in CRC remain largely unidentified.
• Understanding these interactions is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To identify novel miRNAs targeting the Mutated in Colorectal Cancer (MCC) gene.
• To investigate the role of identified miRNAs in colorectal cancer cell behavior and response to chemotherapy.
• To evaluate the therapeutic potential of targeting these miRNAs in colorectal cancer.

Main Methods:

• Array-based miRNA profiling of metastatic versus non-metastatic colorectal cancer tissues.
• Bioinformatic prediction of miRNA targets using miRDB.
• In vitro studies using colorectal cancer cell lines (HCT116, HT29) with miRNA mimics and inhibitors.
• Analysis of gene expression (MCC, SMAD4) and cell behavior (proliferation, migration, apoptosis).
• In vivo studies using a mouse xenograft model.

Main Results:

• miR-4260 was identified as a dysregulated miRNA in colorectal cancer tissues.
• miR-4260 mimic enhanced proliferation and migration while reducing apoptosis induced by 5-fluorouracil in CRC cells.
• miR-4260 directly targets and negatively regulates MCC and SMAD4 by binding to their 3'UTRs.
• Inhibition of miR-4260 reduced tumor growth in vivo.
• miR-4260 upregulation correlated with MCC and SMAD4 downregulation in human CRC tissues.

Conclusions:

• miR-4260 acts as an oncomiR in colorectal cancer by targeting MCC and SMAD4.
• Inhibition of miR-4260 demonstrates therapeutic potential for colorectal cancer treatment.
• Targeting miR-4260 represents a promising novel strategy for colorectal cancer therapy.